The current recommendation is based on the protocol of eligible RCTs, in which the injection of the investigated insulins is all administrated at bedtime. There is insufficient direct evidence to compare the effectiveness and safety among glargine U‐300, degludec U‐100, glargine U‐100, and detemir injected in the morning; there is no eligible evidence to compare morning versus bedtime injection for glargine U‐300 or degludec U‐100 individually in T2DM patients who initially injected basal insulins. Future high‐quality RCTs are required to solve these issues. The gene discussed is INS; the disease is type 2 diabetes mellitus.